NVO Stock Analysis: Buy, Sell, or Hold?
NVO - Novo-Nordisk A/S
$49.22
-0.06 (-0.13%)
▼
5d:
-0.86%
30d:
+11.95%
90d:
+29.58%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Smart Money Accumulation
None View Scanner →
Strength: 7.0/10
Get Alerted When NVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NVO this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NVO shows positive signals but monitor for confirmation. Market pricing in 3.9% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: NVO shows positive signals but monitor for confirmation. Market pricing in 3.9% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$47.16
Based on 1.2% avg growth
INTRINSIC VALUE TODAY
$29.28
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVO is currently trading at $49.22, which is considered slightly high relative to its 30-day fair value range of $43.62 to $49.27. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.3) compared to its historical average (2.1). At these levels, the market is pricing in 3.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NVO is in a strong downtrend. The price is currently testing key support at $47.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVO is in a strong downtrend. The price is currently testing key support at $47.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$43.62 -
$49.27
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.4%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($47.88)
- NEUTRAL: Market pricing in 3.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$43.62 -
$49.27
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$47.87
Resistance Level
$50.90
Current Trend
Strong Downtrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.32
Wall Street Target
$47.88
(-2.8%)
Revenue Growth (YoY)
24.0%
Earnings Growth (YoY)
67.1%
Profit Margin
37.2%
Valuation Premium vs History
+3.9% premium
PE vs Historical
2.3 vs 2.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.9%
(market-implied from PE analysis)
1-Year Target
$51.20
(+4%)
2-Year Target
$53.20
(+8%)
3-Year Target
$55.27
(+12%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$50.01
(+2%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -1.7%)
$438.67
(+790%)
Base:
(SPY PE: 2.3, Growth: -1.7%)
$46.75
(-5%)
Bear:
(PE: 2.0, Growth: -1.7%)
$39.74
(-19%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 11.87 | Current EPS (TTM): $4.17
Bull Case
$108.86
(+121%)
Analyst growth 100.0%, PE expands to 13.1
Base Case
$98.96
(+101%)
Market implied 100.0%, PE stable at 11.9
Bear Case
$33.65
(-32%)
Severe decline -20.0%, PE contracts to 10.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 3:37 PM ET
Data refreshes hourly during market hours. Next update: 4:37 PM
Data refreshes hourly during market hours. Next update: 4:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1240 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 65 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$263 | 58 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$223 | 59 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$356 | 56 HOLD |
Advanced NVO Option Strategies
Professional options setups generated by AI based on today's NVO price and gamma walls.
